Literature DB >> 19444752

A personal light-treatment device for improving sleep quality in the elderly: dynamics of nocturnal melatonin suppression at two exposure levels.

Mariana G Figueiro1, Andrew Bierman, John D Bullough, Mark S Rea.   

Abstract

Light treatment has been used as a non-pharmacological tool to help mitigate poor sleep quality frequently found in older people. In order to increase compliance to non-pharmacological light treatments, new, more efficacious light-delivery systems need to be developed. A prototype personal light-treatment device equipped with low brightness blue light-emitting diodes (LEDs) (peak wavelength near 470 nm) was tested for its effectiveness in suppressing nocturnal melatonin, a measure of circadian stimulation. Two levels of corneal irradiance were set to deliver two prescribed doses of circadian light exposure. Eleven older subjects, between 51 and 80 yrs of age who met the selection criteria, were exposed to a high and a low level of light for 90 min on separate nights from the personal light-treatment device. Blood and saliva samples were collected at prescribed times for subsequent melatonin assay. After 1 h of light exposure, the light-induced nocturnal melatonin suppression level was about 35% for the low-light level and about 60% for the high-light level. The higher level of blue light suppressed melatonin more quickly, to a greater extent over the course of the 90 min exposure period, and maintained suppression after 60 min. The constant exposure of the low-light level resulted in a decrease in nocturnal melatonin suppression for the last sampling time, whereas for the high-light level, suppression continued throughout the entire exposure period. The present study performed with healthy adults suggests that the tested personal light-treatment device might be a practical, comfortable, and effective way to deliver light treatment to those suffering from circadian sleep disorders; however, the acceptance and effectiveness of personal light-treatment devices by older people and by other segments of the population suffering from sleep disorders in a real-life situation need to be directly tested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444752      PMCID: PMC2774221          DOI: 10.1080/07420520902927809

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  46 in total

1.  Age-related changes of circadian rhythms and sleep-wake cycles.

Authors:  In-Young Yoon; Daniel F Kripke; Jeffrey A Elliott; Shawn D Youngstedt; Katharine M Rex; Richard L Hauger
Journal:  J Am Geriatr Soc       Date:  2003-08       Impact factor: 5.562

2.  Circadian rest-activity rhythm disturbances in Alzheimer's disease.

Authors:  E J van Someren; E E Hagebeuk; C Lijzenga; P Scheltens; S E de Rooij; C Jonker; A M Pot; M Mirmiran; D F Swaab
Journal:  Biol Psychiatry       Date:  1996-08-15       Impact factor: 13.382

3.  Sleep fragmentation in patients from a nursing home.

Authors:  S Ancoli-Israel; L Parker; R Sinaee; R L Fell; D F Kripke
Journal:  J Gerontol       Date:  1989-01

4.  A two process model of sleep regulation.

Authors:  A A Borbély
Journal:  Hum Neurobiol       Date:  1982

5.  A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care.

Authors:  C G Lyketsos; L Lindell Veiel; A Baker; C Steele
Journal:  Int J Geriatr Psychiatry       Date:  1999-07       Impact factor: 3.485

6.  Treatment of sleep disturbance in Alzheimer's disease.

Authors:  Susan M. McCurry; Charles F. Reynolds; Sonia Ancoli-Israel; Linda Teri; Michael V. Vitiello
Journal:  Sleep Med Rev       Date:  2000-12       Impact factor: 11.609

7.  Light-induced melatonin suppression in humans with polychromatic and monochromatic light.

Authors:  Victoria L Revell; Debra J Skene
Journal:  Chronobiol Int       Date:  2007       Impact factor: 2.877

8.  Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin D-dimer in older caregivers of people with Alzheimer's disease.

Authors:  Roland von Känel; Joel E Dimsdale; Sonia Ancoli-Israel; Paul J Mills; Thomas L Patterson; Christine L McKibbin; Christopher Archuleta; Igor Grant
Journal:  J Am Geriatr Soc       Date:  2006-03       Impact factor: 5.562

9.  Life between clocks: daily temporal patterns of human chronotypes.

Authors:  Till Roenneberg; Anna Wirz-Justice; Martha Merrow
Journal:  J Biol Rhythms       Date:  2003-02       Impact factor: 3.182

10.  Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice.

Authors:  S Hattar; R J Lucas; N Mrosovsky; S Thompson; R H Douglas; M W Hankins; J Lem; M Biel; F Hofmann; R G Foster; K-W Yau
Journal:  Nature       Date:  2003-06-15       Impact factor: 49.962

View more
  5 in total

1.  Age-related neuroendocrine and alerting responses to light.

Authors:  Sarah L Chellappa; Vivien Bromundt; Sylvia Frey; Christian Cajochen
Journal:  Geroscience       Date:  2021-02-26       Impact factor: 7.713

2.  Increased sensitivity to light-induced melatonin suppression in premenstrual dysphoric disorder.

Authors:  Barbara L Parry; Charles J Meliska; Diane L Sorenson; Ana Lopez; Luis Fernando Martínez; Richard L Hauger; Jeffrey A Elliott
Journal:  Chronobiol Int       Date:  2010-08       Impact factor: 2.877

3.  Circadian light.

Authors:  Mark S Rea; Mariana G Figueiro; Andrew Bierman; John D Bullough
Journal:  J Circadian Rhythms       Date:  2010-02-13

4.  Implications of controlled short-wavelength light exposure for sleep in older adults.

Authors:  Mariana G Figueiro; Natalia Z Lesniak; Mark S Rea
Journal:  BMC Res Notes       Date:  2011-09-08

5.  Differential impact in young and older individuals of blue-enriched white light on circadian physiology and alertness during sustained wakefulness.

Authors:  Virginie Gabel; Carolin F Reichert; Micheline Maire; Christina Schmidt; Luc J M Schlangen; Vitaliy Kolodyazhniy; Corrado Garbazza; Christian Cajochen; Antoine U Viola
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.